Viking Therapeutics' VK5211 successful in mid-stage hip fracture study; shares up 18% premarket [Seeking Alpha]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Seeking Alpha
Viking Therapeutics' VK5211 successful in mid-stage hip fracture study; shares up 18% premarketViking Therapeutics (NASDAQ:VKTX) is up18% premarket on light volume in response to itsannouncement of positive results from a Phase 2 clinical trial assessing VK5211 in patients with recent hip fractures. The study met its primary endpoint of a statistically significant increase in lean body mass, less head compared to placebo. Key secondary endpoints were also met.On the safety front, no drug-related serious adverse events were observed.VK5211, the company's lead program for muscle and bone disorders, is an orally available, non-steroidal selective androgen receptor modulator designed to selectively stimulate muscle and bone formation with reduced activity in peripheral tissues such as skin and prostate.Management will host a conference call momentarily to discuss the results.Previously:Viking Therapeutics completes enrollment in Phase 2 study of VK5211 in patients recovering from hip frac
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- 11 Oversold MidCap Stocks To Buy Now [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics, Inc. (NASDAQ: VKTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.MarketBeat
- Viking Therapeutics, Inc. (NASDAQ: VKTX) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdatePR Newswire
VKTX
Earnings
- 4/24/24 - Beat
VKTX
Sec Filings
- 4/25/24 - Form 10-Q
- 4/24/24 - Form 8-K
- 4/5/24 - Form ARS
- VKTX's page on the SEC website